Armour Thyroid Compounding Legal Status

How Armour Thyroid Reached the Market Without Traditional FDA Approval

Armour Thyroid entered U.S. commerce decades before the modern drug approval framework existed. The product traces back to 1897, when Armour & Company began processing porcine thyroid glands for therapeutic use. Because it was already on the market when the 1938 Federal Food, Drug, and Cosmetic Act (FDCA) took effect, it was never required to submit a New Drug Application (NDA) in the way that post-1938 drugs must 1.

This does not mean Armour Thyroid is illegal. The FDA has historically exercised enforcement discretion toward pre-1938 drugs that meet current good manufacturing practice (cGMP) standards and comply with USP monographs. A 2006 FDA compliance policy guide outlined the agency's approach: products with long marketing histories and acceptable safety profiles could remain available while the agency prioritized enforcement against higher-risk unapproved drugs 1.

The distinction matters clinically. Armour Thyroid is manufactured under cGMP in FDA-inspected facilities. Each batch must conform to USP potency specifications for Thyroid Tablets. The product carries an NDC number, appears in the FDA's National Drug Code Directory, and is dispensed through licensed pharmacies with a prescription 2. It is, in practice, regulated. It simply never went through the NDA review pathway that drugs like levothyroxine sodium (Synthroid, Unithroid) eventually completed.

Levothyroxine itself has a parallel history worth noting. Synthetic T4 products were also marketed for decades without formal NDA approval. The FDA required levothyroxine manufacturers to submit NDAs by 2001, and approved products like Synthroid (2002) and Levoxyl (2003) followed 3. No equivalent mandate has been issued for desiccated thyroid products.

What the Armour Thyroid Label Actually Contains

The label specifies a fixed-ratio combination of T4 and T3 derived from porcine thyroid glands, standardized to USP specifications. Each grain (60 mg) provides approximately 38 mcg of levothyroxine (T4) and 9 mcg of liothyronine (T3) 4.

That T4:T3 ratio of roughly 4.22:1 differs substantially from the human thyroid's secretion ratio. The healthy human thyroid produces T4 and T3 at approximately a 14:1 ratio 5. This means Armour Thyroid delivers proportionally more T3 per dose than the human gland would release. The clinical significance of this difference has been debated for decades.

The label lists available strengths from 15 mg (quarter grain) through 300 mg (5 grains). Standard dosing typically begins at 30 mg daily, titrated based on TSH and clinical response. The label carries warnings about cardiovascular risk at supratherapeutic doses and contraindications for uncorrected adrenal insufficiency.

One label detail that prescribers sometimes overlook: Armour Thyroid tablets contain dextrose, calcium stearate, sodium starch glycolate, and opadry white as inactive ingredients. Patients with celiac disease or severe dextrose sensitivity should be aware of these excipients, though the quantities per tablet are small.

The American Thyroid Association (ATA) 2014 guidelines noted that "the use of a preparation with a T4:T3 ratio closer to physiological secretion, such as a compounded product, could theoretically offer advantages over current fixed-ratio NDT products, although clinical data supporting this are lacking" 6.

Federal Compounding Law: Sections 503A and 503B

Compounded desiccated thyroid preparations are legal in the United States, but the regulatory framework depends on who does the compounding. Two sections of the FDCA govern this space.

Section 503A covers traditional compounding pharmacies. A pharmacist may compound a thyroid preparation for an individual patient based on a valid prescription from a licensed prescriber. The compound must use bulk drug substances that meet USP or National Formulary standards, and the pharmacy cannot compound "essentially a copy" of a commercially available product in anticipation of prescriptions. This last condition is where compliance becomes complex 7.

Section 503B, created by the Drug Quality and Security Act of 2013 (DQSA), established outsourcing facilities. These are compounders that register with the FDA, submit to regular inspections, and may produce larger batches without individual prescriptions. They must follow cGMP requirements and report adverse events. A 503B facility can compound desiccated thyroid preparations and distribute them to healthcare facilities and, in some states, directly to patients 7.

Thyroid USP appears on the FDA's bulk drug substances list that may be used in compounding under both 503A and 503B 8. This is a point of confusion for some patients and prescribers who assume that compounded thyroid exists in a legal gray area. It does not. The substance itself is permissible. The legality question centers on whether the compounder follows the applicable section's requirements.

Why Some Patients and Prescribers Choose Compounded NDT Over Armour

Three clinical scenarios commonly drive prescribers toward compounded desiccated thyroid rather than the branded product.

The first is dose customization. Armour Thyroid is available in fixed increments. A patient who responds best to 45 mg daily (between the 30 mg and 60 mg tablets) would need to split tablets, which is imprecise given the product's coating. A compounding pharmacy can prepare exact-dose capsules.

The second is T4:T3 ratio adjustment. As Hoang et al. documented in a 2013 crossover study of 70 hypothyroid patients, those treated with desiccated thyroid extract (DTE) showed higher T3 and lower T4 serum levels compared to levothyroxine alone, with DTE-treated patients losing an average of 2.86 pounds more than the LT4 group (P = 0.02) 5. Some clinicians want to modify the T4:T3 ratio closer to the physiologic 14:1 range while still using glandular-derived hormone. Compounding makes this possible.

The third involves excipient sensitivities. Patients who react to specific inactive ingredients in Armour Thyroid can receive compounded versions with alternative fillers. This is a legitimate 503A use case because the compound is not "essentially a copy" when the formulation is meaningfully different for a specific patient's needs.

Dr. Antonio Bianco, a thyroid researcher at the University of Chicago, has stated: "The question is not whether desiccated thyroid works. It clearly does for some patients. The question is whether we can improve on the fixed T4:T3 ratio to better match individual physiology" 5.

Quality and Safety Differences Between Branded and Compounded NDT

The safety gap between Armour Thyroid and compounded NDT centers on manufacturing oversight. Branded Armour Thyroid is produced under cGMP in FDA-inspected facilities with batch-to-batch potency testing against USP standards. A 2009 analysis of commercially available thyroid tablets found that brand-name NDT products generally met USP potency specifications of 90% to 110% of labeled hormone content 9.

Compounded preparations, particularly from 503A pharmacies, face less rigorous batch testing. A 2017 study examining compounded thyroid preparations found that 10 out of 12 samples (83%) fell outside the USP potency range for at least one hormone component, with T3 content varying from 71.4% to 135.5% of the labeled amount 10. That variability carries clinical risk. Excess T3 can provoke atrial fibrillation, bone loss, and anxiety. Insufficient T3 defeats the purpose of choosing combination therapy.

Section 503B outsourcing facilities occupy a middle ground. They must follow cGMP, report adverse events to the FDA, and submit to inspections. Their quality record, while imperfect, is measurably better than traditional 503A pharmacies for batch consistency.

The FDA's MedWatch system and Sentinel initiative track adverse events for both branded and compounded thyroid products, though reporting rates for compounded drugs remain lower due to the absence of mandatory adverse event reporting for 503A pharmacies 1.

Patients switching between branded Armour Thyroid and a compounded preparation (or vice versa) should have TSH and free T4/T3 levels rechecked 6 to 8 weeks after the switch, treating it as a new titration event.

State-Level Regulations That Affect Access

Federal law sets the floor for compounding oversight, but states add their own requirements. The result is a patchwork of rules that affect whether and how patients can obtain compounded desiccated thyroid.

Some states restrict 503A pharmacies from shipping compounded prescriptions across state lines. Others limit the percentage of a pharmacy's total business that can consist of compounded products. A few states have adopted stricter potency testing requirements for compounded hormones, partly in response to the 2012 New England Compounding Center (NECC) meningitis outbreak that killed 76 people and sickened 753, though that tragedy involved injectable steroids rather than oral thyroid preparations 11.

California's Board of Pharmacy, for example, requires compounding pharmacies to conduct potency testing on a defined percentage of their preparations. Texas allows 503A pharmacies broader distribution authority than many states. Patients who order compounded thyroid by mail should verify that the dispensing pharmacy holds a valid license in the patient's state of residence.

The National Association of Boards of Pharmacy (NABP) maintains an accreditation program for compounding pharmacies. Choosing a pharmacy with NABP accreditation or Pharmacy Compounding Accreditation Board (PCAB) certification offers patients an additional quality signal beyond minimum state licensure.

The FDA's Evolving Position on Desiccated Thyroid Products

The FDA has not signaled any intent to withdraw Armour Thyroid from the market. The agency's 2006 initiative targeting unapproved drugs focused on products posing clear safety risks or lacking sufficient marketing history, and desiccated thyroid was not among them 1.

A more relevant regulatory development is the FDA's ongoing review of bulk drug substances eligible for compounding. The agency maintains and periodically updates lists of substances that may or may not be compounded under 503A and 503B. Thyroid USP has remained on the permissible list through multiple review cycles 8. There is no active FDA rulemaking proposing its removal.

The ATA's 2014 guidelines recommended levothyroxine monotherapy as the standard of care for hypothyroidism but acknowledged that "a trial of combination therapy (LT4/LT3) might be considered for patients on LT4 who have persistent symptoms despite serum TSH values within the reference range" 6. This guideline position, while not endorsing NDT specifically, creates clinical space for both Armour Thyroid and compounded alternatives.

The European Thyroid Association (ETA) published a 2012 position statement noting insufficient evidence to recommend NDT over LT4 but calling for "properly designed clinical trials" comparing the two approaches 12. That call has been only partially answered in the years since.

Practical Guidance for Patients Considering Compounded Thyroid

Patients currently taking Armour Thyroid who want to explore compounded alternatives should begin by confirming whether the switch addresses a real clinical problem: intolerance to excipients, a need for dose precision that tablet splitting cannot achieve, or a prescriber's decision to adjust the T4:T3 ratio. Switching without a defined reason introduces variability without benefit.

For those who proceed, request a 503B outsourcing facility when possible. Ask the compounding pharmacy for a certificate of analysis (COA) for the specific batch, showing T4 and T3 potency results against labeled values. A reputable pharmacy will provide this without hesitation.

Monitor thyroid labs (TSH, free T4, free T3) at 6 and 12 weeks after any formulation change. Hoang et al. found that patients on desiccated thyroid extract had mean TSH levels of 2.9 mIU/L compared to 2.5 mIU/L on levothyroxine (P = 0.07), a nonsignificant difference that still underscores the importance of individual monitoring 5.